US › Healthcare

Skye Bioscience, Inc. Common Stock (SKYE)

US · Healthcare · Biotechnology

$1.57-7.65%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-10.8M

EPS

$-0.27

EPS estimate

$-0.29

EPS came in at -0.27 against a street estimate of -0.29 — a beat of 6.9%.

Key statistics

Market cap

$9.0M

Forward P/E

0.0

P/B

1.96

Book value

$-0.11

EPS (TTM)

$-10.24

52-week high

$4.99

52-week low

$0.26

50-day MA

$3.85

200-day MA

$6.04

Beta

2.90

Analyst view

Analysts rate Skye Bioscience, Inc. Common Stock a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $68.00.

Shareholding

Insiders

4.24%

Institutions

44.50%

Largest institutional holders

Fund	Stake
5AM Venture Management, LLC	27.33%
Versant Venture Management LLC	5.67%
Baker Bros Advisors LP	4.45%
Vanguard Capital Management, LLC	2.16%
Sphera Funds Management Ltd.	1.92%
BlackRock Inc	0.81%
Geode Capital Management, LLC	0.78%
Junked Platinum Investment Management Ltd	0.66%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Skye Bioscience, Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.